Back to results
US 2005/0233456 A1Published application
In vivo production of cyclic peptides
AssigneeRigel Pharmaceuticals, Inc.
InventorTodd Kinsella
Life of this patent
Estimating the term…
Abstract
The present invention relates ti methods and compositions utilizing inteins to generated libraries of cyclic peptides in vivo.
Claims37
1-58. (canceled)
A retroviral vector comprising a nucleotide sequence encoding a fusion polypeptide comprising, from N-terminus to C-terminus:
- a) a C-terminal domain of an intein;
- b) a peptide;
- c) an N-terminal domain of an intein;
- wherein the amino acid sequence of said intein or region thereof is obtained from a bacteria or yeast and wherein said fusion protein is capable of undergoing a reaction to cyclize said peptide to produce a cyclic peptide in a mammalian cell.
1 more element
A retroviral vector comprising a nucleotide sequence encoding a fusion polypeptide comprising, from N-terminus to C-terminus:
- a) a C-terminal domain of an intein;
- b) a random peptide;
- c) an N-terminal domain of an intein;
- wherein the amino acid sequence of said intein or a region thereof is obtained from Synechocystis and wherein said fusion protein is capable of undergoing a reaction to cyclize said peptide to produce a cyclic peptide in a mammalian cell.
1 more element
(canceled)
Dependencies are inferred from the claim text.